Phase I trial of weekly trabectedin (ET-743) and gemcitabine in patients with advanced solid tumors
- 85 Downloads
To determine the maximum tolerated dose (MTD) of trabectedin plus gemcitabine administered on a weekly schedule in patients with advanced solid tumors.
Patients with ECOG performance status 0–1 and adequate organ function were enrolled. On days 1, 8, and 15 of a 28-day cycle, patients received gemcitabine (starting dose, 800 mg/m2) followed by trabectedin (starting dose, 0.3 mg/m2). Strict liver function test treatment criteria were employed to avoid hepatic toxicity seen in previous trabectedin studies. Plasma samples were collected during cycles 1 and 2 for pharmacokinetic analyses.
Fifteen patients received ≥1 dose, with a median of two treatment cycles (range 1–10). The most common drug-related toxicity was hepatic. Dose reductions were required for trabectedin in four (27%) patients and gemcitabine in six (40%) patients. Cycle delays/dose holds were required in 11 (73%) patients and doses above trabectedin 0.4 mg/m2 and gemcitabine 1,000 mg/m2, which is the recommended phase II dose, were not feasible. Seven patients maintained stable disease after two cycles. Gemcitabine and trabectedin pharmacokinetics were not altered substantially with concomitant administration.
Given the lack of pharmacokinetic interaction and potential efficacy of trabectedin and gemcitabine combination therapy, further study is warranted with alternate schedules.
KeywordsDose-finding Phase I Gemcitabine Pharmacokinetics Trabectedin
This clinical trial (Study ET-743-USA-7) was sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Raritan, NJ and PharmaMar S.A.U., Madrid, Spain. We would like to thank Tom Verhaeghe for overseeing the bioanalysis of trabectedin and gemcitabine. We would also like to thank Lisa Shannon, PharmD, of Scientific Connexions, for providing medical co-writing and editing services.
- 2.Chu QSC, Schwartz G, Forouzesh B et al (2004) Phase I and pharmacokinetic (PK) study of trabectedin (ET-743) administered as a 1-hour infusion weekly for 3 consecutive weeks every 4 weeks to patients with advanced cancer. Presented at the 2004 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; 28 September–1 October, Geneva, SwitzerlandGoogle Scholar
- 6.Fetterly GJ, Owen JS, Stuychens K et al (2007) Semimechanistic pharmacokinetic/pharmacodynamic model for hepatoprotective effect of dexamethasone on transient transaminitis after trabectidin (ET-743) treatment. Cancer Chemother Phamacol, 9 October (Epub ahead of print)Google Scholar
- 11.Gurtler JS, Goldstein L, Delprete S et al (2005) Trabectedin in third line breast cancer: a multicenter, randomized, phase II study comparing two administration regimens. J Clin Oncol 23:16s. (Abstract 625)Google Scholar
- 21.McMeekin DS, Krasner C, Chan S et al (2005) Final results of a phase II study of weekly trabectedin in second/third line ovarian carcinoma. J Clin Oncol 23:16s. (Abstract 5011)Google Scholar
- 26.Morgan JA, Le Cesne A, Chawla S et al (2007) Randomized phase II study of trabectedin in patients with liposarcoma and leiomyosarcoma(L-sarcomas) after failure of prior anthracyclines (A) and ifosfamide (I). J Clin Oncol 25:18s. (Abstract 10060)Google Scholar
- 28.Puchalski TA, Ryan DP, Garcia-Carbonero R et al (2002) Pharmacokinetics of ecteinascidin 743 administered as a 24-h continuous intravenous infusion to adult patients with soft tissue sarcomas: associations with clinical characteristics, pathophysiological variables and toxicity. Cancer Chemother Pharmacol 50:309–319PubMedCrossRefGoogle Scholar